Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2008

View Archived Issues

Responses seen with PF-00299804 in patients with advanced non-small cell lung cancer

Ardea Biosciences reports on gout and arthritis programs at EULAR

Data on GSK-1363089 in papillary renal carcinoma, gastric cancer presented

New agents for treating neurological disorders disclosed in recent NeuroSearch and reMYND patents

SkyePharma reports results from phase III efficacy study of Flutiform

US WorldMeds reports initial results from phase III clinical trial of lofexidine

PLx Pharma demonstrates bioequivalence with aspirin and PL-2100

Neurocrine completes six-month treatment phase in phase IIb trial of elagolix

GLP-1 Technosphere formulation enhances insulin release and lowers blood glucose in healthy subjects

Ghrelin agonist TZP-101 improves symptoms of gastroparesis in diabetic patients

Moderate improvement in rheumatoid arthritis symptoms with MAPK inhibitor VX-702

Phase I results reported for oncolytic compounds from Bristol-Myers Squibb

Protox granted orphan drug status in Europe for PRX-321 in brain cancer

Cipher's revised CIP-Tramadol ER NDA accepted for review by the FDA

Akesis announces positive results from phase IIa trial of AKP-020 in type 2 diabetes

Pivotal phase III Acurox trial meets primary endpoint

Recent Bristol-Myers Squibb patents report novel therapeutic agents for HCV infection

Novel antiinflammatory agents disclosed in joint AstraZeneca and Bayer Schering Pharma patent

ThromboGenics and BioInvent sign license agreement with Roche for anticancer drug TB-403

EMEA recommends that product information for Pfizer's Exubera include data on lung cancer

Hisamitsu and Kyowa enter joint sales agreement in Japan for HFT-290 for cancer pain

Aastrom to initiate phase II clinical trial of cardiac repair cells in DCM

Boehringer Ingelheim to acquire Actimis Pharmaceuticals

Huya completes pre-IND consultation meeting with the FDA for sulcardine sulfate

Nventa develops proprietary vaccine adjuvant, Poly-ICR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...